Melanoma-associated antigen A4-specific T-cells - Adaptimmune

Drug Profile

Melanoma-associated antigen A4-specific T-cells - Adaptimmune

Alternative Names: MAGE-A4 SPEAR T-cell therapy; MAGE-A4-SPEAR-T-cell-therapy-Adaptimmune; MAGE-A4ᶜ¹º³²T

Latest Information Update: 01 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Adaptimmune
  • Class Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunostimulants; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 15 May 2017 Phase-I clinical trials in Solid tumours (Inoperable/Unresectable; Metastatic disease, Late-stage disease) in USA (IV) (NCT03132922)
  • 13 Mar 2017 Adaptimmune Therapeutics has patents pending for MAGE-A4 SPEAR T-cell therapy in United Kingdom
  • 09 Jan 2017 US FDA approves IND application for MAGE-A4 SPEAR T-cell therapy in Solid tumours (malignant)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top